Loading...
ESMO congress Lung Cancer 20192025-01-28T17:07:04+01:00

ESMO 2019 – Barcelona

 

Lecture Board: Maximilian Hochmair, MD; Stephen Liu, MD; Michaël Duruisseaux, MD, PhD
Medical Writer: Judith Moser, MD

DOWNLOADS

All downloads from ESMO 2019

ESMO 2019 Lung Cancer English

Full report (english)

ESMO 2019 Lung Cancer Mandarin

Full report (mandarin)

ESMO 2019 Lung Cancer Japanese

Full report (japanese)

EXPERT VIDEOS

All videointerviews from ESMO 2018

Filippo de Braud explains what can be achieved with TRK inhibition in TRK-fusion-positive NSCLC, indirectly compares the performance of entrectinib to crizotinib in ROS1-positive disease and shares his opinion on the intracranial activity of entrectinib.

Michael Duruisseaux gives an overview on the role of NRG1 gene fusion in the tumorigenesis of lung cancer, the clinical experience with targeted treatment and the importance of molecular testing with respect to NRG1 fusions.

Stephen Liu on the latest insights in the field of ALK-targeted treatment in lung cancer, a recent update on the clinical evaluation of NRG1-directed therapies, as well as novel molecular targets for lung cancer treatment in the foreseeable future.

Ioannis Metaxas talks about the rationale for the evaluation of lurbinectedin in malignant pleural mesothelioma, the clinical results with lurbinectedin in patients with mesothelioma to date and other areas of lung cancer treatment in which lurbinectedin might prove useful in the future.

Immunotherapy improves outcomes when administered together with other therapies such as cytotoxic agents, but also appears to combine well with antiangiogenic drugs based on synergy at the tumor microenvironment level. These insights might fuel new therapeutic algorithms, particularly in patients without driver mutations.

Michaël Duruisseaux • MD • PhD, Respiratory Department, Hôpital Louis Pradel Hospices Civiles de Lyon Cancer Institute Lyon, France
Go to Top